# Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

> **NCT05024214** · PHASE1,PHASE2 · RECRUITING · sponsor: **3D Medicines (Sichuan) Co., Ltd.** · enrollment: 170 (estimated)

## Conditions studied

- Solid Tumors
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib + Envafolimab
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT05024214
- **Lead sponsor:** 3D Medicines (Sichuan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024214, "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05024214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*